List of Excipients in Branded Drug COSENTYX

« Back to Dashboard

Cosentyx Excipient Strategy and Commercial Opportunities

Last updated: October 12, 2026

Cosentyx (secukinumab) uses a relatively short excipient system designed for monoclonal-antibody stability, high-concentration subcutaneous delivery, and compatibility with prefilled injection devices. The core formulation contains histidine buffering agents, trehalose dihydrate, polysorbate 80, and water for injection. Its commercial opportunity is shifting from basic excipient supply toward high-concentration biologic formulation, low-particle surfactant systems, device compatibility, biosimilar development, and intravenous delivery.

What excipients are used in Cosentyx?

The U.S. formulation uses four principal excipient components:

Excipient	Functional role	Commercial relevance
L-histidine	Primary buffer	Controls formulation pH and supports protein stability
L-histidine hydrochloride monohydrate	Conjugate buffer component	Maintains buffer capacity during storage
Trehalose dihydrate	Nonreducing sugar and stabilizer	Protects secukinumab during storage and reduces aggregation risk
Polysorbate 80	Nonionic surfactant	Limits interfacial adsorption and agitation-induced particle formation
Water for injection	Vehicle	Provides the injectable aqueous phase

Cosentyx is supplied as a sterile, preservative-free solution. The formulation is used in prefilled syringes, Sensoready pens, UnoReady pens in certain markets, and intravenous presentations approved for selected indications. Exact concentrations and presentation-specific excipient quantities are controlled by the applicable regulatory label.[1][2]

Why does Cosentyx use histidine buffering?

Histidine is widely used in monoclonal-antibody formulations because it provides buffering near mildly acidic pH ranges while generally maintaining protein solubility and chemical stability. The combination of free histidine and histidine hydrochloride creates a controlled buffer system.

For secukinumab, histidine supports a liquid formulation that can remain stable during refrigerated storage without relying on a lyophilized cake. That simplifies administration and reduces reconstitution steps for patients and health-care providers.

Why is trehalose used in Cosentyx?

Trehalose is a nonreducing disaccharide that stabilizes proteins by replacing some of the hydrogen-bonding interactions normally provided by water. It can reduce structural perturbation during thermal stress, freezing, and drying.

Its role is particularly relevant to a biologic intended for long-term liquid storage and self-injection. Trehalose also has a relatively low chemical reactivity compared with reducing sugars, which reduces the risk of glycation-related degradation.

Why is polysorbate 80 used?

Polysorbate 80 protects secukinumab from adsorption to manufacturing equipment, syringes, cartridges, and air-liquid interfaces. It also reduces aggregation caused by agitation during transportation and device use.

Polysorbate 80 creates a separate control problem. Oxidation and hydrolysis can produce degradation products, including free fatty acids and subvisible particles. These risks make surfactant quality, peroxide control, storage conditions, and supplier consistency important parts of the Cosentyx commercial supply chain.[3]

What formulation strategy does Cosentyx use?

Cosentyx uses a minimalist liquid formulation rather than a complex excipient platform. This strategy has four commercial advantages:

1. It reduces the number of raw materials requiring qualification.
2. It supports ready-to-use injection devices.
3. It limits excipient-related regulatory complexity.
4. It provides a practical platform for multiple dose strengths and administration routes.

The principal formulation challenge is balancing protein concentration, viscosity, particle control, syringeability, and device performance. Secukinumab is administered subcutaneously at doses that can require 150 mg or 300 mg. A formulation that is stable in a vial may not perform equally well in a pen or prefilled syringe.

How does high-concentration delivery affect excipient selection?

Higher protein concentration can increase viscosity, aggregation risk, opalescence, and injection force. The excipient system must preserve chemical and physical stability without making the product difficult to deliver through a narrow-gauge needle.

Cosentyx’s commercial formulation therefore creates demand for:

• Low-peroxide polysorbate 80
• High-purity histidine and histidine hydrochloride
• Low-endotoxin trehalose
• Extractables and leachables testing for syringes and cartridges
• Low-shear filling and pumping equipment
• Device-specific stability studies
• Subvisible-particle and silicone-oil control

The value of these inputs is higher than their commodity price suggests because a change in excipient grade can trigger comparability studies, stability work, container-closure testing, and regulatory submissions.

What excipient suppliers could benefit from Cosentyx demand?

The most attractive suppliers are not necessarily those selling the largest volume. They are suppliers able to provide validated pharmaceutical grades with stable global capacity and strong documentation.

Polysorbate 80 suppliers

Commercial opportunities include:

• Low-peroxide polysorbate 80
• Highly characterized fatty-acid profiles
• Improved oxidation resistance
• Low-particle grades
• Single-use manufacturing formats
• Global regulatory support

Polysorbate 80 suppliers compete on impurity control, lot-to-lot consistency, traceability, and the ability to support biologics manufacturers during post-approval changes.

Trehalose suppliers

Trehalose demand is supported by its use in antibodies, vaccines, cell therapies, and other protein products. Opportunities include:

• Injectable-grade trehalose dihydrate
• Improved control of bioburden and endotoxin
• Regional manufacturing redundancy
• Packaging that limits moisture uptake
• Supply contracts supporting commercial-scale biologics production

Trehalose is less differentiated chemically than a specialized surfactant, but regulatory qualification creates switching costs once a supplier is embedded in a commercial biologic process.

Histidine suppliers

Histidine and histidine hydrochloride are established pharmaceutical excipients. The commercial opportunity is strongest where suppliers can provide:

• Consistent buffer capacity
• Low metal and peroxide contamination
• Injectable-grade documentation
• Global compendial compliance
• Reliable supply during biologics manufacturing expansion

What formulations are protected by Cosentyx intellectual property?

Cosentyx protection is likely distributed across several categories rather than one excipient patent:

Protection category	Relevance to Cosentyx
Antibody composition claims	Protect secukinumab or related anti-IL-17A antibodies
Biological activity claims	Cover binding to IL-17A and inhibition of IL-17 signaling
Therapeutic method claims	Cover treatment of psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and other approved conditions
Formulation claims	May cover concentration, pH, stabilizers, surfactants, and storage conditions
Device claims	May cover pen, syringe, cartridge, or injection-system configurations
Manufacturing claims	May cover cell culture, purification, viral clearance, and antibody production processes

The excipient system itself may not be protected as a standalone commercial barrier. The stronger protection usually comes from the combination of antibody claims, treatment claims, formulation parameters, and device implementation.

Are Cosentyx excipients publicly patent-protected?

Some formulation features may be disclosed in patents or patent applications, but disclosure does not establish that a live, enforceable claim covers the marketed product. Claim scope depends on prosecution history, terminal disclaimers, patent-term adjustment, validity, and jurisdiction.

The core patent review should therefore compare:

• The marketed excipient concentrations
• Claimed pH ranges
• Protein concentration ranges
• Surfactant identity and concentration
• Stabilizer identity
• Container-closure limitations
• Approved administration routes
• Patent expiration and regulatory exclusivity

The FDA does not list biologic products in the Orange Book in the same manner as small-molecule drugs. Biologic reference-product and biosimilar information is primarily handled through the Purple Book.[4]

When does Cosentyx lose regulatory exclusivity?

Cosentyx received FDA approval in January 2015 under Biologics License Application 125504. The reference product received 12 years of reference-product exclusivity under the Biologics Price Competition and Innovation Act, subject to applicable pediatric exclusivity rules.[1][4]

Milestone	Date or status
Original FDA approval	January 21, 2015
Twelve-year reference-product exclusivity	Generally reaches January 21, 2027
Potential pediatric extension	Can add six months if statutory requirements are satisfied
Biosimilar filing pathway	Available under the 351(k) pathway, subject to statutory timing rules
Interchangeability	Requires separate FDA determination for a biosimilar

Regulatory exclusivity is separate from patent protection. A biosimilar may be blocked by an unexpired patent even after reference-product exclusivity expires.

Are there Paragraph IV challenges to Cosentyx?

Paragraph IV certifications apply to listed patents for small-molecule products under the Abbreviated New Drug Application process. Cosentyx is a biologic, so a conventional Abbreviated New Drug Application and Orange Book Paragraph IV strategy do not apply.

A competitor seeking to copy Cosentyx would generally pursue a 351(k) biosimilar application. The relevant legal process is the patent information exchange and litigation framework under the Biologics Price Competition and Innovation Act, often called the patent dance.[4]

This distinction matters commercially. The competitive threat is not a standard generic launch based solely on an ANDA approval. It is a biosimilar launch constrained by:

• Reference-product exclusivity
• Patent litigation
• Interchangeability requirements
• Manufacturing comparability
• Immunogenicity data
• Commercial contracting with payers and providers

What FDA-approved delivery routes increase Cosentyx commercial value?

The original commercial model centered on subcutaneous delivery. FDA later expanded Cosentyx into additional indications and approved an intravenous formulation for certain adult patients with active psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis.[1]

The intravenous presentation increases the value of formulation and manufacturing know-how because it must satisfy different requirements for:

• Infusion dilution
• In-use stability
• Hospital preparation
• Infusion-device compatibility
• Microbial control
• Administration time
• Clinical dosing flexibility

The expansion also increases demand for excipient systems that remain stable after dilution or during controlled infusion preparation.

How strong is the Cosentyx formulation strategy?

The formulation strategy is commercially strong but not necessarily difficult to design around at the excipient level.

Strengths

• Short, familiar excipient list
• Established liquid biologic format
• Compatibility with self-injection devices
• Scalable manufacturing process
• Multiple dose presentations
• Support for subcutaneous and intravenous administration
• Limited use of formulation components that create unusual toxicology issues

Weaknesses

• Polysorbate 80 degradation remains a known biologic-formulation risk
• High-dose delivery can create viscosity and injection-force constraints
• Alternative surfactants may be technically feasible
• Histidine and trehalose are widely used and generally available
• Biosimilar developers can evaluate nonidentical but clinically comparable excipient systems

A biosimilar does not necessarily need to duplicate every inactive ingredient. It must demonstrate analytical, functional, pharmacokinetic, immunogenicity, and, where required, clinical similarity to the reference product. This gives competitors latitude to modify excipients if the changes do not create clinically meaningful differences.

What biosimilar risks exist for Cosentyx?

The leading biosimilar risk is likely to emerge after the reference-product exclusivity period and resolution of relevant patent disputes. The most commercially meaningful differentiation may come from administration and contracting rather than excipient composition.

Potential biosimilar strategies include:

• Maintaining the histidine-trehalose-polysorbate platform
• Substituting polysorbate 20 or another surfactant
• Developing a lower-volume or higher-concentration presentation
• Offering an autoinjector with reduced injection force
• Pursuing interchangeability
• Competing through hospital and payer contracts
• Targeting indications with lower switching barriers

Excipient changes can create a modest technical barrier, but they rarely provide the same protection as a validated device, proprietary manufacturing process, or enforceable patent claim.

What commercial opportunities exist beyond supplying Cosentyx excipients?

The most attractive opportunities are adjacent to the formulation rather than limited to raw-material sales.

High-concentration biologic platforms

Suppliers can offer formulation-development services that optimize:

• Viscosity
• Subvisible particles
• Aggregation
• Injection force
• Silicone-oil interactions
• Freeze-thaw stability
• Shipping stress tolerance

Surfactant alternatives

Polysorbate 80 alternatives, including polysorbate 20 and nonionic surfactants with improved oxidation profiles, may gain interest in biosimilar and next-generation IL-17 products. Adoption depends on toxicology, comparability, regulatory precedent, and device performance.

Device-compatible excipient packages

A supplier that can validate excipients with a specific syringe, cartridge, or autoinjector can create a stronger commercial position than a commodity supplier. Device compatibility includes lubricant interaction, particle formation, stopper compatibility, extractables, and injection force.

Intravenous formulation services

The IV presentation creates demand for ready-to-dilute or infusion-compatible biologic formulations. Contract development and manufacturing organizations can monetize work on dilution stability, container compatibility, and hospital-use presentations.

Biosimilar formulation development

Biosimilar developers may seek excipient systems that match Cosentyx performance while avoiding formulation patents or reducing manufacturing cost. Contract laboratories and CDMOs can support analytical similarity, forced degradation, particle characterization, and immunogenicity risk assessment.

How does Cosentyx compare with competing IL-17 drugs?

Product	Active ingredient	Main formulation opportunity	Competitive issue
Cosentyx	Secukinumab	High-dose subcutaneous and IV delivery	Mature reference product with broad indications
Taltz	Ixekizumab	Prefilled delivery and high-concentration biologic formulation	Competes in psoriasis and psoriatic arthritis
Bimzelx	Bimekizumab	Newer formulation and device platforms	Dual IL-17A/IL-17F mechanism
Siliq	Brodalumab	Subcutaneous biologic delivery	Different IL-17 receptor mechanism
Tremfya	Guselkumab	Subcutaneous and IV development opportunities	IL-23 mechanism and expanding indications

Cosentyx has a broad commercial base and multiple administration formats. Newer competitors can differentiate through dosing intervals, device ergonomics, formulation concentration, indication coverage, or contracting.

What revenue exposure is tied to the Cosentyx formulation?

Cosentyx generated approximately $6 billion in annual sales for Novartis in 2024, making it one of the company’s largest products.[5] The formulation supports revenue across:

• Dermatology
• Rheumatology
• Gastroenterology
• Self-injection
• Infusion-center administration
• Multiple dose strengths
• Global markets

The commercial exposure to excipient disruption is therefore material even though excipients represent a small percentage of product cost. A shortage, quality deviation, or supplier change involving polysorbate 80, trehalose, or histidine could affect batch release, regulatory filings, and device production.

What manufacturing barriers protect Cosentyx beyond excipients?

The strongest manufacturing barriers include:

• Mammalian cell-culture process control
• Antibody purification
• Viral clearance
• Aggregate removal
• Low-particle filling
• Aseptic processing
• Device assembly
• Cold-chain distribution
• Stability data across global markets

A biosimilar developer can purchase the same excipients but still face substantial development work to reproduce the reference product’s critical quality attributes. These include charge variants, glycosylation, aggregation, potency, binding kinetics, and subvisible-particle profiles.

What is the geographic coverage of Cosentyx formulation opportunities?

Cosentyx is marketed across major biologic markets, including the United States, European Union, Japan, and other regions. Commercial opportunities vary by jurisdiction:

• United States: Purple Book, BLA supplements, biosimilar litigation, device regulation
• European Union: centralized marketing authorization and biosimilar pathway
• Japan: PMDA review and local manufacturing or supply requirements
• Emerging markets: price-sensitive biologic access, local fill-finish, and cold-chain constraints

Excipient suppliers with multi-region compendial documentation and redundant manufacturing sites are better positioned than suppliers dependent on one production location.

Key Takeaways

• Cosentyx uses histidine, histidine hydrochloride, trehalose dihydrate, polysorbate 80, and water for injection.
• The formulation is optimized for a stable liquid biologic and ready-to-use delivery devices.
• Polysorbate 80 quality and degradation control are the most technically sensitive excipient issues.
• Trehalose and histidine are commercially important but relatively replaceable components.
• Cosentyx is a biologic, so Orange Book and traditional Paragraph IV analysis do not apply.
• Reference-product exclusivity generally reaches January 2027, subject to any applicable pediatric extension.
• Biosimilar competition will depend more on patents, comparability, devices, interchangeability, and payer access than on excipient cost.
• The highest-value opportunities are high-concentration biologic formulation, device compatibility, low-particle surfactants, IV preparation, and biosimilar development support.
• Cosentyx’s multibillion-dollar sales base makes excipient continuity and change-control management commercially important.

FAQs About Cosentyx Excipients and Commercial Strategy

Does Cosentyx contain polysorbate 80?

Yes. Polysorbate 80 is used as a nonionic surfactant to reduce protein adsorption and aggregation during storage, handling, and injection.

Can a Cosentyx biosimilar use different excipients?

Yes. A biosimilar may use a different excipient system if it demonstrates sufficient analytical and clinical similarity and does not create meaningful differences in safety, purity, potency, or immunogenicity.

Is Cosentyx an Orange Book-listed drug?

No. Cosentyx is a biologic licensed under a BLA. Reference-product and biosimilar information is handled through the FDA’s Purple Book rather than the conventional Orange Book pathway.

Which Cosentyx excipient has the greatest supply-chain risk?

Polysorbate 80 generally presents the greatest technical risk because oxidation, hydrolysis, peroxide content, and particle formation can affect biologic stability and batch quality.

Can excipient patents block a Cosentyx biosimilar?

They can if a live patent contains enforceable claims covering the biosimilar’s formulation, concentration, administration method, or manufacturing process. The analysis requires claim-level review by jurisdiction.

References

1. U.S. Food and Drug Administration. (2024). Cosentyx (secukinumab) prescribing information.
2. European Medicines Agency. (2024). Cosentyx: European public assessment report.
3. International Council for Harmonisation. (2023). ICH Q5C: Quality of biotechnological products: Stability testing of biotechnological/biological products.
4. U.S. Food and Drug Administration. (2024). Purple Book: Lists of licensed biological products with reference product exclusivity and biosimilarity or interchangeability evaluations.
5. Novartis AG. (2025). Annual report 2024.